Advertisement

A Case Report of Torsade de Pointes and Brugada Pattern Associated with Loperamide Misuse and Supratherapeutic Loperamide Concentrations

  • Mark Simon
    Correspondence
    Reprint Address: Mark Simon, MD. Department of Emergency Medicine, Denver Health and Hospital Authority, 777 Bannock Street, MC #0108, Denver, CO 80204.
    Affiliations
    Department of Emergency Medicine, Denver Health and Hospital Authority, Denver, Colorado
    Search for articles by this author
  • John Rague
    Affiliations
    Department of Emergency Medicine, Denver Health and Hospital Authority, Denver, Colorado

    Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, Colorado
    Search for articles by this author

      Abstract

      Background

      Loperamide, commonly sold under the brand name Imodium® (Johnson & Johnson, Fort Washington, PA), is a widely available, over-the-counter antidiarrheal medication that possesses µ-opioid agonist properties and can have catastrophic cardiac events when misused or abused. Since the start of the opioid epidemic in the United States, there has been an increasing number of case reports and deaths linking loperamide abuse with cardiac events such as torsades de pointes (TdP) and Brugada syndrome.

      Case Report

      This case report presents a 22-year-old man who presented in cardiac arrest from polymorphic ventricular tachycardia consistent with TdP and a Type 1 Brugada pattern after intentional loperamide abuse. We discuss this patient's management and the proposed pathophysiology of these two cardiotoxicities, of which, to our knowledge, no previously published case report has displayed both in the same patient after a supratherapeutic loperamide ingestion.

      Why Should an Emergency Physician Be Aware of This?

      As the prevalence of opioid dependency and misuse has increased, so, too, has the misuse of un-scheduled medications such as loperamide to achieve central nervous system opioid effects. It is important for the emergency physician to know about and understand loperamide-associated cardiotoxicities such as prolongation of the QRS, unmasking of Brugada patterns, QT prolongation, or ventricular dysrhythmias such as TdP to be able to recognize and treat it.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Katz KD
        • Cannon RD
        • Cook MD
        • et al.
        Loperamide-induced torsades de pointes: a case series.
        J Emerg Med. 2017; 53: 339-344
        • Dierksen J
        • Gonsoulin M
        • Walterscheid JP.
        Poor man's methadone: a case report of loperamide toxicity.
        Am J Forensic Med Pathol. 2015; 36: 268-270
        • Stefek B
        • Wolfe LT
        • Cohen M.
        Brugada syndrome associated with adolescent loperamide abuse.
        Pediatrics. 2018; 142e20181423
        • Vakkalanka JP
        • Charlton NP
        • Holstege CP.
        Epidemiologic trends in loperamide abuse and misuse.
        Ann Emerg Med. 2017; 69: 73-78
        • Lasoff DR
        • Koh CH
        • Corbett B
        • et al.
        Loperamide trends in abuse and misuse over 13 years: 2002–2015.
        Pharmacotherapy. 2017; 37: 249-253
        • Bishop-Freeman SC
        • Feaster MS
        • Beal J
        • et al.
        Loperamide-related deaths in North Carolina.
        J Anal Toxicol. 2016; 40: 677-686
        • Daniulaityte R
        • Carlson R
        • Falck R
        • et al.
        I just wanted to tell you that loperamide WILL WORK": a web-based study of extra-medical use of loperamide.
        Drug Alcohol Depend. 2013; 130: 241-244
        • The Vaults of Erowid
        Loperamide, Published May 12, 2016 (Available at:)
        https://erowid.org/pharms/loperamide/
        Date accessed: August 1, 2020
        • Kang J
        • Compton DR
        • Vaz RJ
        • Rampe D.
        Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic.
        Naunyn Schmiedebergs Arch Pharmacol. 2016; 389: 1133-1137
      1. U.S. Food and Drug Administration. Loperamide (marketed as Imodium A-D) information. Published January 29, 2018. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/loperamide-marketed-imodium-d-information. Accessed 2 July 2020.

        • Montesinos RN
        • Moulari B
        • Gromand J
        • et al.
        Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution.
        Drug Metab Dispos. 2014; 42: 700-706
        • Baker DE.
        Loperamide: a pharmacological review.
        Rev Gastroenterol Disord. 2007; 7 (suppl): S11-S18
        • Kim KA
        • Chung J
        • Jung DH
        • Park JY.
        Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes.
        Eur J Clin Pharmacol. 2004; 60: 575-581
        • MacDonald R
        • Heiner J
        • Villarreal J
        • Strote J.
        Loperamide dependence and abuse.
        BMJ Case Rep. 2015; 2015bcr2015209705
        • Sadeque AJ
        • Wandel C
        • He H
        • et al.
        Increased drug delivery to the brain by P-glycoprotein inhibition.
        Clin Pharmacol Ther. 2000; 68: 231-237
        • Eggleston W
        • Nacca N
        • Marraffa JM.
        Loperamide toxicokinetics: serum concentrations in the overdose setting.
        Clin Toxicol (Phila). 2015; 53: 495-496
        • Arcangelo VP
        • Peterson AM
        • Wilbur VF
        • Reinhold JA
        Pharmacotherapeutics for advanced practice: a practical approach.
        4th edn. Lippincott Williams and Wilkins, Philadelphia, PA2016
        • Sanguinetti MC
        • Jiang C
        • Curran ME
        • Keating MT.
        A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
        Cell. 1995; 81: 299-307
        • Sun C
        • Brice JA
        • Clark RF.
        Brugada-type pattern on electrocardiogram associated with high-dose loperamide abuse.
        J Emerg Med. 2018; 54: 484-486
        • Rojas SF
        • Oglat A
        • Bonilla HMG
        • et al.
        Loperamide mimicking Brugada pattern.
        Methodist Debakey Cardiovasc J. 2018; 14: e1-e3
        • Leung G
        • Altshuler D.
        Conduction disturbances and ventricular arrhythmias associated with high-dose loperamide.
        J Clin Toxicol. 2016; 6 (doi:10.4172/2161-0495.1000309)
        • Bebarta VS
        • Phillips S
        • Eberhardt A
        • Calihan K
        • Waksman JC
        • Heard K.
        Incidence of Brugada electrocardiographic pattern and outcomes of these patients after intentional tricyclic antidepressant ingestion.
        Am J Cardiol. 2007; 100: 656-660
        • Shimizu W
        • Antzelevitch C
        • Suyama K
        • et al.
        Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome.
        J Cardiovasc Electrophysiol. 2000; 11: 1320-1329
      2. GPD1L glycerol-3-phosphate dehydrogenase 1 like [Homo sapiens (human)]. Gene ID: 2819 [updated 6-May-2021]. Available at: https://www.ncbi.nlm.nih.gov/gene?Db&Cmd=DetailsSearch&Term=2819. Accessed 18 May 2021.

        • London B
        • Michalec M
        • Mehdi H
        • et al.
        Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias.
        Circulation. 2007; 116: 2260-2268
        • Huang H
        • Chen YQ
        • Fan LL
        • et al.
        Whole-exome sequencing identifies a novel mutation of GPD1L (R189X) associated with familial conduction disease and sudden death.
        J Cell Mol Med. 2018; 22: 1350-1354
      3. Lists of: Scheduling Actions Controlled Substances Regulated Chemicals. (Accessed 3 July 2020), 2020.